AndreaBozzo/ceres-open-data-index huggingface dataset:
Considerations and Challenges for County-Administered States in Discussing CCWIS

States are currently reviewing the new Comprehensive Child Welfare Information System (CCWIS) regulations and assessing the impacts these requirements will have on their existing child welfare information systems. Join us as representatives from Colorado, New York, and Virginia discuss the unique considerations and challenges that countyâadministered states face as they discuss a potential CCWIS implementation. Included are the following topics:

This session will be participant driven, with state representatives sharing their experiences and much of the session devoted to Q&A and open discussion. Although the discussion focuses on countyâadministered states, this webinar is open to all states. Speakers for the session will include the following:

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 525892: N,N-Dimethyl-N'-(4-nitrophenyl)-isobutyramidine

Chemical compound data from PubChem database. IUPAC Name: N,N,2-trimethyl-N'-(4-nitrophenyl)propanimidamide. Molecular Formula: C12H17N3O2. Molecular Weight: 235.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525103: 1,3-Dichloroisopropyl propionate

Chemical compound data from PubChem database. IUPAC Name: 1,2-dichloropropan-2-yl propanoate. Molecular Formula: C6H10Cl2O2. Molecular Weight: 185.05. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400942-T1: [Translated] METHOD AND DEVICE FOR ALLOCATING A TRANSMISSION TIME SLOT IN A WIRELESS COMMUNICATIONS SYSTEM AND SYSTEM THEREOF

An apparatus and method is provided for efficiently allocating a transmission period in a WLAN system. An access point (AP) transmits a PSMP message providing a downlink period and an uplink period provided to each station (STA), and at least one sub PSMP frame indicating a period of at least one of a downlink and an uplink for an STA requiring additional resource allocation. After exchanging data with the AP in the downlink and uplink periods provided by the PSMP frame, if there is a need for additional resource allocation, the STA receives the at least one sub PSMP frame and exchanges data with the AP in the period provided by the each sub PSMP frame.
Compound 526293: 1,4,7,8-Tetrabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,4,7,8-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529797: Norleucine, N-trifluoroacetyl, 1-methylethyl ester

Chemical compound data from PubChem database. IUPAC Name: propan-2-yl 2-[(2,2,2-trifluoroacetyl)amino]hexanoate. Molecular Formula: C11H18F3NO3. Molecular Weight: 269.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Incidence Tables (Prevalence Estimates) - 4.1 to 4.16

These detailed tables present totals and prevalence estimates of substance use initiation from the 2012 National Survey on Drug Use and Health (NSDUH). Substances examined include illicit drugs (e.g., marijuana, cocaine, heroin, hallucinogens (including LSD, PCP, Ecstasy), inhalants, and the nonmedical use of prescription-type pain relievers (including OxyContin), tranquilizers, stimulants, sedatives, alcohol, and tobacco products (including cigarettes, smokeless tobacco, and cigars). Results are provided by age group and gender. Estimates are provided for both 2012 and 2011
Compound 530005: Norethandrolone metabolite, di-trimethylsilyl

Chemical compound data from PubChem database. IUPAC Name: (17-ethyl-13-methyl-3-trimethylsilyloxy-2,3,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)oxy-trimethylsilane. Molecular Formula: C26H50O2Si2. Molecular Weight: 450.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525382: 2,5,6-Trimethyl-3,4-dithiaheptane

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-3-(propan-2-yldisulfanyl)butane. Molecular Formula: C8H18S2. Molecular Weight: 178.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401768-T1: [Translated] DEVICE FOR FACILITATING USE OF STANDARD ELECTRONIC COMPONENTS IN HARSH ENVIRONMENTS

An apparatus is provided for permitting commercial-off-the-shelf (COTS) electronics to be utilized in harsh environments for which the COTS electronics are not designed, including environments having ambient temperature variations, ambient pressure variations, shock and vibration exposure, environmental contaminants and/or electromagnetic radiation which may be beyond the design specification of the COTS components. The device includes a sealed enclosure having racks or other suitable mounts for the COTS components and having an environmental controlled unit (ECU) which circulates a fluid such as air through the enclosure and through the mounts. The temperature in the enclosure is monitored and the ECU operated to heat or cool fluid passing therethrough to maintain temperature in the enclosure within the design limits of the COTS electronics. A flow channel for ambient fluid, which channel is sealed from the internally circulating fluid, may be provided for removing heat from a cooling unit of the ECU. The enclosure may also have shock mounts, thermal insulation and appropriate shielding to deal with other environmental concerns.
Patent AT-E401064-T1: [Translated] RELEASE OF ANTIEMETICS BY INHALATION ROUTE

The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antipsychotic. In a method aspect of the present invention, an antipsychotic is delivered to a mammal through an inhalation route. The method comprises: a) Heating a composition, wherein the composition comprises at least 5 percent by weight of an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an antipsychotic; and, b) a device that forms an antipsychotic containing aerosol from the composition, for inhalation by the mammal.
Anti-atherogenic effects of fibrates in type 2 diabetes

Type 2 diabetes is an increasing cause of premature coronary heart disease. Several trials with lipid-modifying therapy have included sufficient numbers of diabetics to indicate that treatment of diabetic dyslipidaemia with either fibrates or statins reduces the risk of future coronary events in such patients. However, until recently no reported study had been designed specifically to investigate the effects of intervening in patients with type 2 diabetes. The Diabetes Atherosclerosis Intervention Study (DAIS) is an angiographic study in which 418 diabetic subjects were randomized to micronised fenofibrate or placebo groups. After 3 years of treatment, the fenofibrate group had a significantly reduced rate of progression of coronary atherosclerosis. This study, when considered with the results of other studies that have included diabetics, has important implications for the treatment of diabetic dyslipidaemia. The evidence that is currently available supports a place for both fibrates and statins, either as monotherapy or in combination, in the treatment of diabetic dyslipidaemia.
Publications Using SAMHSA DataTobacco Product and Alcohol Use Tables (Standard Errors and P Values) - 2.1 to 2.84

These detailed tables present standard errors for totals and prevalence estimates of tobacco and alcohol use from the 2011 National Survey on Drug Use and Health (NSDUH). Tobacco products include cigarettes, smokeless tobacco, cigars, and pipe tobacco. Alcohol use includes binge and heavy alcohol use. Standard errors are provided for lifetime, past year, and past month use by age group, gender, race/ethnicity, education level, employment status, and geographic area. Standard errors are provided for both 2011 and 2010.
Fundamentals of Change and Implementation in Child Welfare Information Systems

A discussion about strategies to strengthen system adoption and implementation. This webinar, co-hosted with the Capacity Building Center for States, highlights a new tool, Mapping Change and Implementation to Comprehensive Child Welfare Information System (CCWIS) Projects, and how it may be used in different project phases.

Additional information and the tool can be found at: Mapping Change and Implementation to CCWIS Projects - Center for States - Child Welfare Capacity Building Collaborative (PDF), and the PDF is also available in the files below.

Audio Description Version

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E401411-T1: [Translated] ßFROG-PRINCEß - A TRANSPOSON VECTOR FOR GENE TRANSFER IN VERTEBRATES

The present invention relates to a transposon-based DNA integration system comprising (a) a transposon which is devoid of a polynucleotide encoding a functional transposase and which comprises a polynucleotide of interest, wherein the transposon comprises inverted repeats having a degree of identity with the repeats within SEQ ID NO: 2 and its inverted repeat, respectively, of at least 90%; and (b) a transposase having at its N-terminus a DNA binding domain comprising the sequences of SEQ ID NO: 3 and 4; or (c) a polynucleotide encoding the transposase of (b). The present invention further relates to a method of transferring a polynucleotide of interest into cells of a vertebrate comprising the step of introducing the transposon-based DNA integration system of the invention into said cells. In addition, the invention relates to a method of effecting RNAi comprising (a) stably introducing a transposon comprising an expression cassette expressing a short interfering RNA and a selectable marker gene as part of the transposon-based DNA integration system of the invention into a cell; (b) selecting for cells expressing the selectable marker; and (c) assessing whether the transcription/translation of the desired gene is effected by RNAi. A further embodiment of the invention is a method of gene trapping genes comprising the steps of (a) introducing the transposon-based DNA integration system of the invention into a cell; and (b) assessing for the expression of a selectable marker wherein expression of a selectable marker is indicative of integration of the transposon into a transcibed gene of the cell.
Sex steroids do not affect shigatoxin cytotoxicity on human renal tubular or glomerular cells

Background
          The greater susceptibility of children to renal injury in post-diarrheal hemolytic-uremic syndrome (HUS) may be related, at least in part, to heightened renal cell sensitivity to the cytotoxic effect of Shiga toxin (Stx), the putative mediator of kidney damage in HUS. We hypothesized that sexual maturation, which coincides with a falling incidence of HUS, may induce a relatively Stx-resistant state in the renal cells.
        
        
          Methods
          Cultured human glomerular endothelial (HGEN), human glomerular visceral epithelial (HGEC) and human proximal tubule (HPT) cells were exposed to Stx-1 after pre-incubation with progesterone, β-estradiol or testosterone followed by determination of cytotoxicity.
        
        
          Results
          Under basal conditions, Stx-1 potently and dose-dependently killed HPT and HGEC, but had relatively little effect on HGEN. Pre-incubation for 1, 2 or 7 days with physiologic or pharmacologic concentrations of progesterone, β-estradiol or testosterone had no effect on Stx-1 cytotoxicity dose-response on any cell type. In addition, no steroid altered Gb3 expression (Stx receptor) by any cell type at any time point.
        
        
          Conclusion
          These data do not support the notion that hormonal changes associated with puberty induce an Stx-resistant state within kidney cells.
Compound 529416: 2,3,4,5-Tetrakis(trimethylsilyloxy)pentanal

Chemical compound data from PubChem database. IUPAC Name: 2,3,4,5-tetrakis(trimethylsilyloxy)pentanal. Molecular Formula: C17H42O5Si4. Molecular Weight: 438.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Supporting Kinship Caregivers Part 2

This Child Welfare Information Gateway Podcast is available on Apple Podcasts
  
  

, GooglePlay
  
  

, Spotify
  
  

, Stitcher
  
  

, SoundCloud
  
  

, and the Child Welfare Information Gateway
  
  

 website. Subscribe to receive new episodes as they are released.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E400856-T1: [Translated] SYSTEMS AND METHODS FOR SORTING AND DELIVERY OF PACKAGES USING RFID TECHNOLOGY

A disclosed method comprises scanning a radio-frequency identification (RFID) tag on a package to generate scanned data, and generating a handling instruction for the package based on the scanned data. The handling instruction can be executed to route the package to a tip position within a hub facility for directing the package to the next location along its route, and/or to pre-load the package in a vehicle for delivery to the package's final destination. Related systems and computer-readable media are also disclosed.
MHC class I multimers

T lymphocytes play a key role in the immune response to both foreign and self peptide antigens, which they recognize in combination with MHC molecules. In the past it has been difficult to analyse objectively the specificity, frequency and intensity of T cell responses. The recent application of fluorescent-labelled MHC class I multimers, however, has provided a powerful experimental approach to the direct visualisation of antigen-specific T cells. As a result, our perspective of how T cells respond to both viruses and other antigens in vivo has been greatly enhanced.
New York City – 5 Boros: Drug-Related Emergency Department Visits, 2004-2011 - All Misuse and Abuse

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving drug misuse or abuse in New York City (5 boroughs), covering 2004-2011. Drug misuse/abuse visits include the use of illicit drugs, nonmedical use of pharmaceuticals, underage drinking and visits where alcohol was combined with another drug.
NNDSS - TABLE 1PP. Viral hemorrhagic fevers, Sabia virus to Zika virus disease, non-congenital

NNDSS - TABLE 1PP. Viral hemorrhagic fevers, Sabia virus to Zika virus disease, non-congenital – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Maryland (MD)

This report presents Maryland\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Maryland for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Moxifloxacin

Moxifloxacin Hydrochloride is a generic antibiotic tablet used to treat certain bacterial infections. Each film-coated tablet contains 400 mg of moxifloxacin hydrochloride and is taken orally. Manufactured by Dr. Reddy's Laboratories Limited under ANDA 076938, it's available in prescription form. This information was generated using AI and is provided for informational and research purposes only.
Localities for 2010B

Payment files reflect a change in the conversion factor as a result of the Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010, which President Obama signed into law on June 25, 2010. This legislation provides for a 2.2 percent update to the 2010 Medicare Physician Fee Schedule (MPFS), effective for dates of service June 1, 2010, through November 30, 2010. For 2010A: Payment files reflect changes as a result of practice expense (PE) and malpractice (MP) relative value unit (RVU) corrections and provisions of the Patient Protection and Affordable Care Act (the Affordable Care Act), as modified by the Health Care and Education Reconciliation Act of 2010, which President Obama signed into law on March 23, 2010, and March 30, 2010, respectively.
Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C

Background
          The standard of care for HCV Hepatitis is the combination of interferon (IFN) plus Ribavirin. In HIV patients the use of this combination therapy may induce drug interactions, and reduces the adherence to HAART.
          The aim of this study is to evaluate safety and efficacy of a 48 weeks daily dose IFN schedule.
        
        
          Methods
          We evaluated 50 coinfected patients; alpha IFN 2a was administered at a dose of 3 MU daily. The baseline values were the following : CD4+ 515 cells/mmc (mean); HIV-RNA <50 copies/ml in all patients; HCV-RNA 28, 3 × 106 copies/ml.
        
        
          Results
          At 48 weeks, 10 patients (20%) achieved a biochemical and virological response according to an intention to treat analysis.
          Twenty four patients (48%) underwent a drop-out mainly by side effects related to overlapping toxicity of interferon and antiretroviral therapy. All the patients, who responded to the treatment, showed a fast relapse one month after the end of treatment.
        
        
          Conclusion
          Although our results demonstrated a very poor outcome and a bad tolerance to interferon monotherapy, this approach should not be dropped out, mainly in patients at high risk for side effects and in those with cirrhosis who do not tolerate or are at increased risk for the use of ribavirin.
Patent AT-E400585-T1: [Translated] GPI ANCHORED GLYCOPROTEIN ACA AS A NEW TUMOR MARKER

Described is a GPI-anchored surface glycoprotein having a GPI-anchor which is characterized by a non-acetylated inositol ring and diacyl glycerol as lipid tail of the anchor. A particular glycoprotein of the invention, ACA, is strongly expressed in melanoma cells and some leukemia cells, thus, is an useful marker for diagnosis of said tumors. The invention also relates to salts, functional derivatives and active fractions of ACA having substantially the same spectrum of biological activities of ACA. The invention also relates to a process for the purification of ACA, to its cloning and its production by recombinant DNA techniques. It further relates to diagnostic compositions comprising an anti-ACA-antibody or an oliognucleotide probe capable of hybridizing to ACA-mRNA and to pharmaceutical compounds containing a compound capable of reducing the expression of ACA or the activity of the protein.
QHP Landscape Instructions PY2024 Dental SHOP

The Dental SHOP Market file of the QHP Landscape Files contains information on certified dental plans offered through an Exchange to employers in the Small Business Health Options Program (SHOP) market. These plans are also known as Stand-alone Dental Plans (SADPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.
Compound 526759: Naphthalene, 1,2,3,4,6-pentamethyl

Chemical compound data from PubChem database. IUPAC Name: 1,2,3,4,6-pentamethylnaphthalene. Molecular Formula: C15H18. Molecular Weight: 198.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.